Submitted for Publication: January 27, 2012; final revision received July 9, 2012; accepted July 16, 2012.
Published Online: January 9, 2013. doi:10.1001/2013.jamapsychiatry.55
Author Contributions: All authors had full access to all of the data in the study. Dr Kessler takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of Interest Disclosures: Dr Kessler has been a consultant for AstraZeneca, the Analysis Group, Bristol-Myers Squibb, Cerner-Galt Associates, Eli Lilly and Co, GlaxoSmithKline, HealthCore Inc, Health Dialog, Integrated Benefits Institute, John Snow Inc, Kaiser Permanente, Matria Inc, Mensante, Merck and Co Inc, Ortho-McNeil Janssen Scientific Affairs, Pfizer Inc, Primary Care Network, Research Triangle Institute, sanofi-aventis, Shire US Inc, SRA International Inc, Takeda Global Research and Development, Transcept Pharmaceuticals Inc, and Wyeth-Ayerst Laboratories; he has served on advisory boards for Appliance Computing II, Eli Lilly and Co, Mindsite, Ortho-McNeil Janssen Scientific Affairs, and Wyeth-Ayerst Laboratories; and he has received research support for his epidemiological studies from the Analysis Group, Bristol-Myers Squibb, Eli Lilly and Co, EPI-Q, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Janssen Scientific Affairs, Pfizer Inc, sanofi-aventis, and Shire US Inc.
Funding/Support: The NCS-A is supported by grants U01-MH60220, R01-MH66627, U01MH060220-09S1, K01-MH092526 (to Dr McLaughlin), and K01-MH085710 (to Dr Green) from the National Institute of Mental Health, with supplemental support from the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, grant 044780 from the Robert Wood Johnson Foundation, and the John W. Alden Trust. The World Mental Health Data Coordination Centres have been supported by grants R01-MH070884, R13-MH066849, R01-MH069864, and R01-MH077883 from the National Institute of Mental Health, grant R01-DA016558 from the National Institute on Drug Abuse, grant FIRCA R03-TW006481 from the Fogarty International Center of the National Institutes of Health, the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the Pan American Health Organization, and unrestricted educational grants from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Ortho-McNeil, Pfizer, sanofi-aventis, and Wyeth.
Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the opinions of any of the sponsoring organizations, agencies, or the US government.
Additional Information: A complete list of NCS-A publications can be found at http://www.hcp.med.harvard.edu/ncs. A public-use version of the NCS-A data set is available for secondary analysis. Instructions for accessing the data set can be found at http://www.hcp.med.harvard.edu/ncs/index.php. A detailed set of subsample prevalence tables has been posted on the NCS website (http://www.hcp.med.harvard.edu/ncs/publications.php) in conjunction with the publication of this article. The NCS-A is carried out in conjunction with the World Health Organization World Mental Health Survey Initiative. A complete list of World Mental Health Survey Initiative publications can be found at http://www.hcp.med.harvard.edu/wmh/.
Additional Contributions: We thank the staff of the World Mental Health Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis.